Oxford Cannabinoid Technologies Holdings Plc is a pharmaceutical company which specializes in cannabinoid drug development with focus on the pain market. Its drug development strategy includes the development of proprietary cannabinoid derivatives, natural phytocannabinoids (pCBs) and other drug compounds that interplay with the endocannabinoid system. The company was founded by Indraneil Mahapatra and Gavin Hilary Sathianathan on March 10, 2017 and is headquartered in London, the United Kingdom.